Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07347691

AI-Based Prediction of Atrial Fibrillation in ESUS Patients With ICM

This study investigates patients with Embolic Stroke of Undetermined Source (ESUS) who have received an Implantable Cardiac Monitor (ICM). The main purpose is to evaluate the predictive value of an Artificial Intelligence ECG analysis tool, named SmartECG-AF.

Participants will be classified into two groups based on the AI analysis: a "High Risk" group and a "Low to Intermediate Risk" (control) group. The study aims to compare the incidence rate of atrial fibrillation (AF) events over time between these two groups. Additionally, the study will analyze the relationship between the AI-predicted risk levels and the occurrence of major cardiovascular events during the follow-up period.

Recruiting

Interested in participating?

Request Info

Key information

Age range

30 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Korea University Ansan Hospital, Ansan, South Korea

Loading trial locations.

About this study

Embolic Stroke of Undetermined Source (ESUS) accounts for a significant proportion of ischemic strokes, and occult Atrial Fibrillation (AF) is considered a major etiology. While Implantable Cardiac Monitors (ICMs) are the gold standard for long-term rhythm monitoring, identifying patients at the highest risk for AF remains a clinical challenge.

This multicenter, prospective study aims to validate the clinical utility of an artificial intelligence-based electrocardiogram analysis algorithm, "SmartECG-AF," in this specific population. The algorithm analyzes 12-lead ECGs recorded during sinus rhythm to detect subtle signs of electrical remodeling associated with paroxysmal AF.

Enrolled patients with ESUS who have undergone ICM implantation will have their baseline ECGs analyzed by the SmartECG-AF algorithm. Based on the AI-generated probability score, patients will be stratified into a "High Risk" group and a "Low to Intermediate Risk" group. The study will longitudinally track these patients to compare the time-to-event for ICM-detected AF between the two groups. Additionally, the study will evaluate the correlation between the AI risk score and the incidence of Major Adverse Cardiovascular Events (MACE), providing evidence for AI-guided risk stratification in cryptogenic stroke management.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients aged 30 years or older.
  • Patients diagnosed with Embolic Stroke of Undetermined Source (ESUS) who have undergone or are scheduled for Implantable Cardiac Monitor (ICM) implantation.
  • Patients who have undergone at least one 12-lead ECG examination within 2 weeks before or after the date of ICM implantation.
  • Patients maintaining Sinus Rhythm on ECG at the time of enrollment.
  • Patients who have voluntarily signed the informed consent form.

Exclusion criteria

  • Patients diagnosed with Atrial Fibrillation (AF) at least once prior to the date of enrollment.
  • Patients whose ICM battery status is at Elective Replacement Interval (ERI), making recording impossible.
  • Patients whose ECGs cannot be analyzed by the AI algorithm (SmartECG-AF) due to severe artifacts or noise, or are incompatible with digital analysis.

Treatment and study plan

Primary outcomes

  1. Incidence of Atrial Fibrillation (Time-to-Event)

    Time frame: Up to 12 months

    Comparison of the cumulative incidence rate of atrial fibrillation (AF) events between the High Risk group and the Low to Intermediate Risk group (classified by SmartECG-AF). AF occurrence is confirmed by reviewing data recorded on the Implantable Cardiac Monitor (ICM).

Secondary outcomes

  1. Incidence of Major Adverse Cardiovascular Events (MACE)

    Time frame: Up to 12 months

    Evaluation of the composite rate of major clinical events including recurrent stroke, hospitalization for heart failure, myocardial infarction, and all-cause death (cardiovascular and non-cardiovascular). The study will analyze the correlation between the occurrence of these events and the AI-predicted risk levels.

Study contacts

Contact information is provided by the study sponsor or research team.

Hyoung Seok Lee, MD

CONTACT

[email protected]

+82-32-890-3575

Yong-Soo Baek, MD, PhD

CONTACT

[email protected]

+82-32-890-2200

Sponsors and collaborators

Lead sponsor

Inha University Hospital

Other

Collaborators

  • DeepCardio Co., Ltd.

Registry information

Official study title

Predicting Atrial Fibrillation in Patients With Post-implantable Cardiac Monitor Implementation : A Prospective, Long-term Follow-up Study Using Comprehensive AI ECG Analysis : Multicenter Prospective Study

Acronym: SMART-ESUS

Important dates

Study start
2025
Primary completion
2027
Study completion
2028
First posted
Jan 16, 2026
Registry last updated
Jan 16, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.